Toll-like receptors in lymphoid malignancies: Double-edged sword

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 2, 2014, Pages 262-283

  Harsini, Sara ^a   Beigy, Maani ^a   Akhavan Sabbagh, Mahsa ^a   Rezaei, Nima ^a,b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Leukemia; Lymphoma; Pattern recognition receptors; Toll like receptors

Indexed keywords

IMIQUIMOD; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; B CELL LYMPHOMA; BIOLOGICAL FUNCTIONS; BURKITT LYMPHOMA; CELL DEATH; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; HODGKIN DISEASE; HUMAN; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LYMPHOMA;

LEUKEMIA; LYMPHOMA; PATTERN RECOGNITION RECEPTORS; TOLL-LIKE RECEPTORS;

ANIMALS; B-LYMPHOCYTES; HUMANS; LEUKEMIA; LYMPHOMA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84892533310     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.010     Document Type: Review

References (262)

1. Chiron D., Bekeredjian-ding I., Pellat-deceunynck C., et al. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 2008, 12:2205-2213.
2. Hedayat M., Takeda K., Rezaei N. Prophylactic and therapeutic implications of Toll-like receptor ligands. Medicinal Research Reviews 2010, 32:294-325.
3. Lee J., Chuang T.-H., Redecke V., et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proceedings of the National Academy of Sciences 2003, 100:6646-6651.
4. Moghimpour Bijani F., Vallejo J.G., Rezaei N. Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities. International Reviews of Immunology 2012, 31:379-395.
5. Wolska A., Lech-maranda E., Robak T. Toll-like receptors and their role in hematologic malignancies. Current Molecular Medicine 2009, 9:324-335.
6. Kawai T., Akira S. TLR signaling. Seminars in Immunology 2007, 19:24-32.
7. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406.
8. Kawai T., Akira S. Signaling to NF-κB by Toll-like receptors. Trends in Molecular Medicine 2007, 13:460-469.
9. Moynagh P.N. TLR signalling and activation of IRFs: revisiting old friends from the NF-κB pathway. Trends in Immunology 2005, 26:469-476.
10. Akira S., Tokeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunology 2001, 2:675-680.
11. Arvaniti E., Ntoufa S., Papakonstantinou N., et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 2011, 96:1644-1652.
12. Pasare C., Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes and Infection 2004, 6:1382-1387.
13. Spaner D.E. Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. Journal of Leukocyte Biology 2004, 76:338-351.
14. Jost P.J., Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
15. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Medicine 2007, 13:552-559.
16. Neill L.A.J.O., Bryant C.E., Doyle S.L. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacological Research 2009, 61:177-197.
17. Rezaei N. Therapeutic targeting of pattern-recognition receptors. International Immunopharmacology 2006, 6:863-869.
18. So E.Y., Ouchi T. The application of Toll like receptors for cancer therapy. International Journal of Biological Sciences 2010, 6:675-681.
19. Spaner D.E., Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007, 21:53-60.
20. Erter J., Alinari L., Darabi K., et al. New targets of therapy in T-cell lymphomas. Current Drug Targets 2010, 11:482-493.
21. Basith S., Manavalan B., Lee G., Kim S.G., Choi S. Toll-like receptor modulators: a patent review (2006-2010). Expert Opinions 2011, 21:927-944.
22. Chang Z. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflammation Research 2010, 59:791-808.
23. Krishnan J., Basith S., Choi S. Advances in Toll-like receptor signaling. Advances in Systems Biology 2012, 1:5-15.
24. Girart M.V., Fuertes M.B., Domaica C.I., Rossi L.E., Zwirner N.W. Engagement of TLR3, TLR7, and NKG2D regulate IFN-γ secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. Journal of Immunology 2007, 179:3472-3479.
25. Holm C.K., Petersen C.C., Hvid M., et al. TLR3 ligand polyinosinic:polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells. Journal of Immunology 2009, 183:4422-4431.
26. Fitzner N., Clauberg S., Essmann F., Liebmann J., Kolb-Bachofen V. Human skin endothelial cells can express all 10 TLR genes and respond to respective ligands. Clinical and Vaccine Immunology 2008, 15:138-146.
27. Pegu A., Qin S., Fallert Junecko B.A., Nisato R.E., Pepper M.S., Reinhart T.A. Human lymphatic endothelial cells express multiple functional TLRs. Journal of Immunology 2008, 180:3399-3405.
28. Miller L.S., Modlin R.L. Human keratinocyte Toll-like receptors promote distinct immune responses. Journal of Investigative Dermatology 2007, 127:262-263.
29. Guo F., Mead J., Aliya N., et al. RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response. PloS ONE 2012, 7:e42583.
30. Jasani B., Navabi H., Adams M. Ampligen: a potential Toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009, 27:3401-3404.
31. Hamm S., Rath S., Michel S., Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. Journal of Immunotoxicology 2009, 6:257-265.
32. Schön M.P., Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008, 27:190-199.
33. Hemmi H., Kaisho T., Takeuchi O., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunology 2002, 3:196-200.
34. Jurk M., Heil F., Vollmer J., et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nature Immunology 2002, 3. 499
35. Weigel B.J., Cooley S., DeFor T., et al. Prolonged subcutaneous administration of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. American Journal of Hematology 2012, 87:953-956.
36. Kronenberger B., Zeuzem S. Current and future treatment options for HCV. Annals of Hepatology 2009, 8:103-112.
37. Greiff L., Cervin A., Ahlstrom-Emanuelsson C., et al. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respiratory Research 2012, 13:53.
38. Wysocka M., Dawany N., Benoit B., et al. Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-gamma: implications for therapy of cutaneous T-cell lymphoma. Leukemia and Lymphoma 2011, 52:1970-1979.
39. Hemmi H., Takeuchi O., Kawai T., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
40. Hornung V., Rothenfusser S., Britsch S., et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. Journal of Immunology 2002, 168:4531-4537.
41. van Ojik H.H., Bevaart L., Dahle C.E., et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Research 2003, 63:5595-5600.
42. Roman M., Martin-Orozco E., Goodman J.S., et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nature Medicine 1997, 3:849-854.
43. Vabulas R.M., Pircher H., Lipford G.B., Hacker H., Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. Journal of Immunology 2000, 164:2372-2378.
44. Krieg A.M., Yi A.K., Matson S., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
45. Yi A.K., Chang M., Peckham D.W., Krieg A.M., Ashman R.F. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. Journal of Immunology 1998, 160:5898-5906.
46. Atanackovic D., Block A., de Weerth A., Faltz C., Hossfeld D.K., Hegewisch-Becker S. Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10:2600-2608.
47. Noack J., Jordi M., Zauner L., et al. TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism. Cell Death and Disease 2012, 3.
48. Köchling J., Prada J., Bahrami M., et al. Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 2008, 26:4669-4675.
49. Agrawal S., Kandimalla E.R. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochemical Society Transactions 2007, 35:1461-1467.
50. Kline J.N., Krieg A.M. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News & Perspectives 2008, 21:434-439.
51. Harandi A.M., Davies G., Olesen O.F. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Review of Vaccines 2009, 8:293-298.
52. Dorn A., Kippenberger S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Current Opinion in Molecular Therapeutics 2008, 10:10-20.
53. Heijink I.H., Van Oosterhout A.J. Strategies for targeting T-cells in allergic diseases and asthma. Pharmacology & Therapeutics 2006, 112:489-500.
54. Musch E., Lutfi T., von Stein P., et al. Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflammatory Bowel Diseases 2013, 19:283-292.
55. Friedberg J.W., Kelly J.L., Neuberg D., et al. study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology 2009, 146:282-291.
56. Friedberg J.W., Kim H., McCauley M., et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005, 105:489-495.
57. Askew D., Chu R.S., Krieg A.M., Harding C.V. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. Journal of Immunology 2000, 165:6889-6895.
58. Galluzzi L., Vacchelli E., Eggermont A., et al. Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012, 1:699-716.
59. Takeuchi O., Sato S., Horiuchi T., et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. Journal of Immunology 2002, 169:10-14.
60. Wyllie D.H., Kiss-Toth E., Visintin A., et al. Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses. Journal of Immunology 2000, 165:7125-7132.
61. Bas S., James R., Gabay C. Serum lipoproteins attenuate macrophage activation and Toll-like receptor stimulation by bacterial lipoproteins. BMC Immunology 2010, 11:46.
62. Guerau-de-Arellano M., Huber B.T. Chemokines and Toll-like receptors in Lyme disease pathogenesis. Trends in Molecular Medicine 2005, 11:114-120.
63. Jin M., Kim S., Heo J., et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007, 130:1071-1082.
64. Goutagny N., Estornes Y., Hasan U., Lebecque S., Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Targeted Oncology 2005, 7:29-54.
65. Kaisho T., Akira S. Regulation of dendritic cell function through Toll-like receptors. Current Molecular Medicine 2003, 3:373-385.
66. Mitchell D., Yong M., Raju J., et al. Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: implications for peptide vaccines. Human Vaccines 2011, 7 Suppl.:85-93.
67. Aliprantis A.O., Yang R.-B., Mark M.R., et al. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 1999, 285:736-739.
68. Singh V.K., Ducey E.J., Fatanmi O.O., et al. CBLB613: a TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. Radiation Research 2012, 177:628-642.
69. Schwandner R., Dziarski R., Wesche H., Rothe M., Kirschning C.J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. Journal of Biological Chemistry 1999, 274:17406-17409.
70. Massari P., Henneke P., Ho Y., et al. Immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. Journal of Immunology 2002, 168:1533-1537.
71. Toussi D.N., Liu X., Massari P., The FomA. The FomA porin from Fusobacterium nucleatum is a Toll-like receptor 2 agonist with immune adjuvant activity. Clinical and Vaccine Immunology - CVI 2012, 19:1093-1101.
72. Hirschfeld M., Weis J.J., Toshchakov V., et al. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infection and Immunity 2001, 69:1477-1482.
73. Werts C., Tapping R.I., Mathison J.C., et al. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nature Immunology 2001, 2:346-352.
74. Jeannin P., Renno T., Goetsch L., et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nature Immunology 2000, 1:502-509.
75. Means T.K., Wang S., Lien E., Yoshimura A., Golenbock D.T., Fenton M.J. Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. Journal of Immunology 1999, 163:3920-3927.
76. Bieback K., Lien E., Klagge I.M., et al. Hemagglutinin protein of wild-type measles virus activates Toll-Like receptor 2 signaling. Journal of Virology 2002, 76:8729-8736.
77. Aravalli R.N., Hu S., Rowen T.N., Palmquist J.M., Lokensgard J.R. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. Journal of Immunology 2005, 175:4189-4193.
78. Compton T., Kurt-Jones E.A., Boehme K.W., et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. Journal of Virology 2003, 77:4588-4596.
79. Underhill D.M., Ozinsky A., Hajjar A.M., et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999, 401:811-815.
80. Li M., Chen Q., Shen Y., Liu W. Candida albicans phospholipomannan triggers inflammatory responses of human keratinocytes through Toll-like receptor 2. Experimental Dermatology 2009, 18:603-610.
81. Lu H., Yang Y., Gad E., et al. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17:67-76.
82. Prakken A.B.J., van Hoeij M.J.W., Kuis W., et al. T-Cell reactivity to human HSP60 in oligo-articular juvenile chronic arthritis is associated with a favorable prognosis and the generation of regulatory cytokines in the inflamed joint. Immunology Letters 1997, 57:139-142.
83. Vabulas R.M., Ahmad-Nejad P., da Costa C., et al. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. Journal of Biological Chemistry 2001, 276:31332-31339.
84. Asea A., Rehli M., Kabingu E., et al. Novel signal transduction pathway utilized by extracellular HSP70. Journal of Biological Chemistry 2002, 277:15028-15034.
85. Vabulas R.M., Ahmad-Nejad P., Ghose S., Kirschning C.J., Issels R.D., Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. Journal of Biological Chemistry 2002, 277:15107-15112.
86. Huang Q.-Q., Sobkoviak R., Jockheck-Clark A.R., et al. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. Journal of Immunology 2009, 182:4965-4973.
87. Vabulas R.M., Braedel S., Hilf N., et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. Journal of Biological Chemistry 2002, 277:20847-20853.
88. Park J.S., Svetkauskaite D., He Q., et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. Journal of Biological Chemistry 2004, 279:7370-7377.
89. Jiang D., Liang J., Fan J., et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nature Medicine 2005, 11:1173-1179.
90. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-[kappa]B by Toll-like receptor 3. Nature 2001, 413:732-738.
91. Kariko K., Ni H., Capodici J., Lamphier M., Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. Journal of Biological Chemistry 2004, 279:12542-12550.
92. Matsumoto M., Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Advanced Drug Delivery Reviews 2008, 60:805-812.
93. MacRedmond R., Greene C., Taggart C.C., McElvaney N., O'Neill S. Respiratory epithelial cells require Toll-like receptor 4 for induction of human beta-defensin 2 by lipopolysaccharide. Respiratory Research 2005, 6:116.
94. Poltorak A., He X., Smirnova I., et al. Signaling in C3H/HeJ and C57BL/10ScCr Mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
95. Bulut Y., Faure E., Thomas L., et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. Journal of Immunology 2002, 168:1435-1440.
96. Rassa J.C., Meyers J.L., Zhang Y., Kudaravalli R., Ross S.R. Murine retroviruses activate B cells via interaction with Toll-like receptor 4. Proceedings of the National Academy of Science 2002, 99:2281-2286.
97. Shingai M., Azuma M., Ebihara T., et al. Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction. International Immunology 2008, 20:1169-1180.
98. Kurt-Jones E.A., Popova L., Kwinn L., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Immunology 2000, 1:398-401.
99. Oliveira A.-C., Peixoto J.R., de Arruda L.B., et al. Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. Journal of Immunology 2004, 173:5688-5696.
100. Kawasaki K., Akashi S., Shimazu R., Yoshida T., Miyake K., Nishijima M. Mouse Toll-like receptor 4 and MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol. Journal of Biological Chemistry 2000, 275:2251-2254.
101. Raghu R., Sharma D., Ramakrishnan R., Khanam S., Chintalwar G.J., Sainis K.B. Molecular events in the activation of B cells and macrophages by a non-microbial TLR4 agonist, G1-4A from Tinospora cordifolia. Immunology Letters 2009, 123:60-71.
102. Roelofs M.F., Boelens W.C., Joosten L.A.B., et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. Journal of Immunology 2006, 176:7021-7027.
103. Termeer C., Benedix F., Sleeman J., et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. Journal of Experimental Medicine 2002, 195:99-111.
104. Johnson G.B., Brunn G.J., Kodaira Y., Platt J.L. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. Journal of Immunology 2002, 168:5233-5239.
105. Smiley S.T., King J.A., Hancock W.W. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. Journal of Immunology 2001, 167:2887-2894.
106. Guillot L.c., Balloy V., McCormack F.X., et al. The immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. Journal of Immunology 2002, 168:5989-5992.
107. Biragyn A., Ruffini P.A., Leifer C.A., et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002, 298:1025-1029.
108. Okamura Y., Watari M., Jerud E.S., et al. The extra domain A of fibronectin activates Toll-like receptor 4. Journal of Biological Chemistry 2001, 276:10229-10233.
109. Baldridge J.R., McGowan P., Evans J.T., et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opinion on Biological Therapy 2004, 4:1129-1138.
110. Shanmugam A., Rajoria S., George A.L., Mittelman A., Suriano R., Tiwari R.K. Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants. PloS ONE 2012, 7:e30839.
111. Lien E., Chow J.C., Hawkins L.D., et al. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/Toll-like receptor 4 signaling pathway. Journal of Biological Chemistry 2001, 276:1873-1880.
112. Przetak M., Chow J., Cheng H., Rose J., Hawkins L.D., Ishizaka S.T. Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine 2003, 21:961-970.
113. Kawata T., Bristol J.R., Rossignol D.P., et al. E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide. British Journal of Pharmacology 1999, 127:853-862.
114. Mullarkey M., Rose J.R., Bristol J., et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. Journal of Pharmacology and Experimental Therapeutics 2003, 304:1093-1102.
115. Palladino M.A., Savarese M.A., Chapman J.L., Dughi M.-K., Plaska D. Original article: localization of Toll-like receptors on epididymal epithelial cells and spermatozoa. American Journal of Reproductive Immunology 2008, 60:541-555.
116. Hayashi F., Smith K.D., Ozinsky A., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
117. Burdelya L.G., Krivokrysenko V.I., Tallant T.C., et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008, 320:226-230.
118. Takeuchi O., Kawai T., Muhlradt P.F., et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. International Immunology 2001, 13:933-940.
119. Henneke P., Takeuchi O., van Strijp J.A., et al. Novel engagement of CD14 and multiple Toll-like receptors by group B streptococci. Journal of Immunology 2001, 167:7069-7076.
120. Ozinsky A., Underhill D.M., Fontenot J.D., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proceedings of the National Academy of Sciences 2000, 97:13766-13771.
121. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531.
122. Heil F., Hemmi H., Hochrein H., et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
123. Barrat F.J., Meeker T., Gregorio J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. Journal of Experimental Medicine 2005, 202:1131-1139.
124. Vollmer, Tluk S., Schmitz C., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. Journal of Experimental Medicine 2005, 202:1575-1585.
125. Stevens M.F., Schwalbe C.H., Patel N., Gate E.N., Bryant P.K. Structural studies on bioactive compounds. Part 26. Hydrogen bonding in the crystal structure of the N-methylformamide solvate of the immunomodulatory agent 2-amino-5-bromo-6-phenylpyrimidin-4-one (bropirimine): implications for the design of novel anti-tumour strategies. Anticancer Drug Design 1995, 10(3):203-213.
126. Hart O.M., Athie-Morales V., O'Connor G.M., Gardiner C.M. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. Journal of Immunology 2005, 175:1636-1642.
127. Lu H., Dietsch G.N., Matthews M.A., et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18:499-509.
128. Horak F. VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opinion on Investigational Drugs 2011, 20:981-986.
129. Coban C., Ishii K.J., Kawai T., et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. Journal of Experimental Medicine 2005, 201:19-25.
130. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
131. Aichinger M.C., Ginzler M., Weghuber J., et al. Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells. Vaccine 2011, 29:426-436.
132. Olafsdottir T.A., Lingnau K., Nagy E., Jonsdottir I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scandinavian Journal of Immunology 2009, 69:194-202.
133. Schellack C., Prinz K., Egyed A., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006, 24:5461-5472.
134. Lauw F.N., Caffrey D.R., Golenbock D.T. Of mice and man: TLR11 (finally) finds profilin. Trends in Immunology 2005, 26:509-511.
135. Yarovinsky F., Zhang D., Andersen J.F., et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005, 308:1626-1629.
136. Takeda K., Akira S. TLR signaling pathways. Seminars in Immunology 2004, 16:3-9.
137. Kawai T., Akira S. TLR signaling. Cell Death and Differentiation 2006, 13:816-825.
138. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
139. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology 1999, 17:3835-3849.
140. Smedby K.E., Askling J., Mariette X., Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas - an update. Journal of Internal Medicine 2008, 264:514-527.
141. Nieters A., Beckmann L., Deeg E., Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes & Immunity 2006, 7:615-624.
142. Smedby K.E., Baecklund E., Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiology, Biomarkers and Prevention 2006, 15:2069-2077.
143. Purdue M.P., Lan Q., Wang S.S., et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009, 30:275-281.
144. Kim E.J., Hess S., Richardson S.K., et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. Journal of Clinical Investigation 2005, 115:798-812.
145. Wysocka M., Benoit B.M., Newton S., Azzoni L., Montaner L.J., Rook A.H. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 2004, 104:4142-4149.
146. Fernandez-Guarino M. Emerging treatment options for early mycosis fungoides. Clinical, Cosmetic and Investigational Dermatology 2013, 6:61-69.
147. Küppers R. New insights in the biology of Hodgkin lymphoma. ASH Education Program Book 2012, 2012:328-334.
148. Kuppers R., Engert A., Hansmann M.L. Hodgkin lymphoma. Journal of Clinical Investigation 2012, 122:3439-3447.
149. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., Wang J.M. Toll-like receptors in inflammation, infection and cancer. International Immunopharmacology 2007, 7:1271-1285.
150. Lazarus R., Raby B.A., Lange C., et al. TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples. American Journal of Respiratory and Critical Care Medicine 2004, 170:594-600.
151. Tantisira K., Klimecki W.T., Lazarus R., et al. Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes & Immunity 2004, 5:343-346.
152. Kesh S., Mensah N.Y., Peterlongo P., et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Annals of the New York Academy of Sciences 2005, 1062:95-103.
153. Ferreri A.J., Zucca E. Marginal-zone lymphoma. Critical Reviews in Oncology/Hematology 2007, 63:245-256.
154. Hussell T., Isaacson P.G., Crabtree J.E., Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993, 342:571-574.
155. Wotherspoon A.C. Gastric MALT lymphoma and Helicobacter pylori. Yale Journal of Biology and Medicine 1996, 69:61-68.
156. Smith M.F., Mitchell A., Li G., et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. Journal of Biological Chemistry 2003, 278:32552-32560.
157. Torok A.M., Bouton A.H., Goldberg J.B. Helicobacter pylori induces interleukin-8 secretion by Toll-like receptor 2- and Toll-like receptor 5-dependent and -independent pathways. Infection and Immunity 2005, 73:1523-1531.
158. Hellmig S., Fischbach W., Goebeler-Kolve M.E., Folsch U.R., Hampe J., Schreiber S. Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leukemia and Lymphoma 2005, 46:869-872.
159. Forrest M.S., Skibola C.F., Lightfoot T.J., et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. British Journal of Haematology 2006, 134:180-183.
160. Wang L., Zhao Y., Qian J., et al. Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion. Cancer 2013, 119:782-791.
161. Carvalho A., Cunha C., Almeida A.J., Osorio N.S., Saraiva M., Teixeira-Coelho M. The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes & Immunity 2012, 13:197-210.
162. Kado J.A., Shango M., Mehregan C., Mehregan D.R. Mapping Toll-like receptor activity in different stages of cutaneous T-cell lymphoma. American Journal of Dermatopathology 2012, 34:691-698.
163. Schmitz R., Stanelle J., Hansmann M.L., Kuppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annual Review of Pathology 2009, 4:151-174.
164. Tiacci E., Döring C., Brune V., et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012, 120:4609-4620.
165. Mollaki V., Georgiadis T., Tassidou A., et al. Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study. Journal of Human Genetics 2009, 54:655-659.
166. Klein-gonzález N., Holtick U., Martin R., Von M.S. Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma. Expert ReviewsVaccines 2011, 10:295-298.
167. Stanley M.A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clinical and Experimental Dermatology 2002, 27:571-577.
168. Schön M.P., Schön M. Imiquimod: mode of action. British Journal of Dermatology 2007, 157(Suppl 2):8-13.
169. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. Journal of Immunology 1991, 147:3815-3822.
170. Rousset F., Garcia E., Defrance T., Peronne C., Vezzio N., Hsu D.H. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:1890-1893.
171. Beatty P.R., Krams S.M., Martinez O.M. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. Journal of Immunology 1997, 158:4045-4051.
172. Jones K.D., Aoki Y., Chang Y., Moore P.S., Yarchoan R., Tosato G. Involvement of interleukin- 10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 1999, 94:2871-2879.
173. Masood R., Zhang Y., Bond M.W., Scadden D.T., Moudgil T., Law R.E. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 1995, 85:3423-3430.
174. Brody J.D., Ai W.Z., Czerwinski D.K., et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. Journal of Clinical Oncology 2010, 28:4324-4332.
175. Rohatiner A.Z.S., Lister T.A. The clinical course of follicular lymphoma. Best Practice and Research Clinical Haematology 2005, 18:1-10.
176. Kohrt H.E., Houot R., Marabelle A., et al. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012, 4:511-527.
177. Moga E., Alvarez E., Cantó E., et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Experimental Hematology 2008, 36:69-77.
178. Pui C.H., Campana D., Evans W.E. Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncology 2001, 2:597.
179. Ross M.E., Zhou X., Song G., et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102:2951-2959.
180. Armstrong S.A., Look A.T. Molecular genetics of acute lymphoblastic leukemia. Journal of Clinical Oncology 2005, 23:6306-6315.
181. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. New England Journal of Medicine 2004, 350:1535-1548.
182. Bassan R. Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia. Haematologica 2005, 90:1299.
183. Iacobucci I., Papayannidis C., Lonetti A., Ferrari A., Baccarani M., Martinelli G. Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. Current Hematologic Malignancy Reports 2012, 7(2):133-143.
184. Pui C.H., Sandlund J.T., Pei D., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004, 104:2690-2696.
185. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. New England Journal of Medicine 2006, 354:166-178.
186. Iacobucci I., Papayannidis C., Lonetti A., Ferrari A., Baccarani M., Martinelli G. Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. Current Hematologic Malignancy Reports 2012, 7:133-143.
187. Corthals S.L., Wynne K., She K., et al. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. British Journal of Haematology 2006, 132:452-458.
188. Reid G.S.D., She K., Terrett L., Food M.R., Trudeau J.D., Schultz K.R. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood 2005, 105:3641-3647.
189. Alessandri A.J., Reid G.S.D., Bader S.A., Massing B.G., Sorensen P.H.B., Schultz K.R. ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. British Journal of Haematology 2002, 116:266-272.
190. Cardoso A.A., Schultze J.L., Boussiotis V.A., et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996, 88:41-48.
191. Yotnda P., Mintz P., Grigoriadou K., Lemonnier F., Vilmer E., Langlade-Demoyen P. Analysis of T-cell defects in the specific immune response against acute lymphoblastic leukemia cells. Experimental Hematology 1999, 27:1375-1383.
192. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer 2005, 5:263-274.
193. Fabricius D., Breckerbohm L., Vollmer A., et al. Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses. Leukemia 2011, 25:1111-1121.
194. Bohnhorst J., Rasmussen T., Moen S.H., et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006, 20:1138-1144.
195. Jego G., Bataille R., Geffroy-Luseau A., Descamps G., Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006, 20:1130-1137.
196. O'Connor B.P., Gleeson M.W., Noelle R.J., Erickson L.D. The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunological Reviews 2003, 194:61-76.
197. Shapiro-Shelef M., Calame K. Plasma cell differentiation and multiple myeloma. Current Opinion in Immunology 2004, 16:226-234.
198. Caers J., De Raeve H., Michaux L., et al. Multiple myeloma-an update on diagnosis and treatment. European Journal of Haematology 2008, 81:329-343.
199. Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2008, 23:3-9.
200. Saraf S., Patel P., Rondelli D. Epidemiology, biology, and outcome in multiple myeloma patients in different geographical areas of the world. Journal of Advances in Internal Medicine 2012, 1(1):20-32.
201. Ludwig H., Durie B.G.M., Bolejack V., et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008, 111:4039-4047.
202. Clark A.D., Shetty A., Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Reviews 1999, 13:79-90.
203. Bladé J., Kyle R.A., Greipp P.R. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. British Journal of Haematology 2003, 93:345-351.
204. Griniute R., Bumblyte I.A. Clinical and laboratory features and prognostic implications in myeloma with and without renal impairment. Medicina (Kaunas, Lithuania) 2003, 39:41.
205. Caligaris-Cappio F., Gregoretti M.G., Merico F., et al. Bone marrow microenvironment and the progression of multiple myeloma. Leukemia and Lymphoma 1992, 8:15-22.
206. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3-21.
207. Xu Y., Zhao Y., Huang H., et al. Expression and function of Toll-like receptors in multiple myeloma patients: Toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-κB. British Journal of Haematology 2010, 150(5):543-553.
208. Seidl S., Kaufmann H., Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncology 2003, 4:557-564.
209. Hideshima T., Richardson P., Anderson K.C. Novel therapeutic approaches for multiple myeloma. Immunological Reviews 2003, 194:164-176.
210. Brenne A.T., Ro T.B., Waage A., Sundan A., Borset M., Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002, 99:3756-3762.
211. Lauta V.M. A review of the cytokine network in multiple myeloma. Cancer 2003, 97:2440-2452.
212. Jacobson D.R., Zolla-Pazner S. Immunosuppression and infection in multiple myeloma 1986, 282.
213. Chiron D., Jego G., Pellat-Deuceunynck C. Toll-like receptors: expression and involvement in multiple myeloma. Leukemia Research 2010, 34:1545-1550.
214. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine 2002, 8:793-800.
215. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunological Reviews 2004, 199:227-250.
216. Pratt G., Goodyear O., Moss P. Immunodeficiency and immunotherapy in multiple myeloma. British Journal of Haematology 2007, 138:563-579.
217. Chauhan D., Singh A.V., Brahmandam M., et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009, 16:309-323.
218. Assaf A., Esteves H., Curnow S.J., Browning M.J. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines. Cellular Immunology 2009, 259:90-99.
219. Sivori S., Falco M., Della Chiesa M., et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:10116-10121.
220. Abbott B.L. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006, 11:21-30.
221. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. New England Journal of Medicine 2005, 352:804-815.
222. Rozková D., Novotná L., Pytlík R., et al. Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. International Journal of Cancer 2010, 126:1132-1143.
223. García-Muñoz R., Galiacho V.R., Llorente L. Immunological aspects in chronic lymphocytic leukemia (CLL) development. Annals of Hematology 2012, 91(7):981-996.
224. Spaner D.E., Shi Y., White D., et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2005, 20:286-295.
225. Jahrsdörfer B., Mühlenhoff L., Blackwell S.E., et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clinical Cancer Research 2005, 11:1490-1499.
226. Longo P.G., Laurenti L., Gobessi S., et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2006, 21:110-120.
227. Shi Y., White D., He L., Miller R.L., Spaner D.E. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Research 2007, 67:1823-1831.
228. Spaner D.E., Miller R.L., Mena J., Grossman L., Sorrenti V., Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leukemia & Lymphoma 2005, 46:935-939.
229. Decker T., Schneller F., Sparwasser T., et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000, 95:999-1006.
230. Jahrsdörfer B., Hartmann G., Racila E., et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. Journal of Leukocyte Biology 2001, 69:81-88.
231. Byrd J.C., Rai K., Peterson B.L., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49-53.
232. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nature Medicine 2004, 10:909-915.
233. Zinkernagel M.R. Immunity against solid tumors?. International Journal of Cancer 2001, 93:1-5.
234. He W., Liu Q., Wang L., Chen W., Li N., Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Molecular Immunology 2007, 44:2850-2859.
235. Hoogendoorn M., Wolbers J.O., Smit W.M., et al. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia 2004, 18:1278-1287.
236. Liang X., Moseman E.A., Farrar M.A., et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010, 115(24):5041-5052.
237. Kawai T., Akira S. Pathogen recognition with Toll-like receptors. Current Opinion in Immunology 2005, 17:338.
238. Li V.W., Li W.W., Talcott K.E., Zhai A.W. Imiquimod as an antiangiogenic agent. Journal of Drugs in Dermatology - JDD 2005, 4:708.
239. Gitelson E., Hammond C., Mena J., et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clinical Cancer Research 2003, 9:1656-1665.
240. Riches J.C., Ramsay A.G., Gribben J.G. Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy. Current Pharmaceutical Design 2012, 18(23):3389-3398.
241. Spaner D.E., Hammond C., Mena J., Foden C., Deabreu A. A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy 2005, 54:635-646.
242. Decker T., Peschel C. Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells. Leukemia & Lymphoma 2001, 42:301-307.
243. Ntoufa S., Vardi A., Papakonstantinou N., et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Molecular Medicine 2012, 18:1281-1291.
244. Coelho P.S., Klein A., Talvani A., et al. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN-gamma-primed-macrophages. Journal of Leukocyte Biology 2002, 71:837-844.
245. Jahrsdörfer B., Jox R., Mühlenhoff L., et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. Journal of Leukocyte Biology 2002, 72:83-92.
246. Tromp J.M., Tonino S.H., Elias J.A., et al. Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010, 29:5071-5082.
247. Zent C.S., Smith B.J., Ballas Z.K., et al. clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leukemia and Lymphoma 2012, 53:211-217.
248. Decker T., Hipp S., Ringshausen I., et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003, 101:278-285.
249. Decker T., Schneller F., Hipp S., et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002, 16:327-334.
250. Tomic J., White D., Shi Y., et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. Journal of Immunology 2006, 176:3830-3839.
251. Goodman M.G., Spinosa J.C., Saven A., Piro L.D., Wormsley S. New perspectives on the approach to chronic lymphocytic leukemia. Leukemia and Lymphoma 1996, 22:1-10.
252. Wang T., Niu G., Kortylewski M., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine 2003, 10:48-54.
253. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nature Reviews Immunology 2006, 6:295-307.
254. Jahrsdörfer B., Wooldridge J.E., Blackwell S.E., et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. Journal of Leukocyte Biology 2005, 77:378-387.
255. Decker T., Hipp S., Kreitman R.J., Pastan I., Peschel C., Licht T. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 2002, 99:1320-1326.
256. Lee J., Chuang T.H., Redecke V., et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proceedings of the National Academy of Sciences 2003, 100:6646-6651.
257. Goodman M.G., Wormsley S.B., Spinosa J.C., Piro L.D. Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle. Blood 1994, 84:3457-3464.
258. Kreitman R.J. Recombinant toxins for the treatment of cancer. Current Opinion in Molecular Therapeutics 2003, 5:44.
259. Henault M., Lee L.N., Evans G.F., Zuckerman S.H. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. Journal of Immunological Methods 2005, 300:93-99.
260. Smith T.J., Yamamoto K., Kurata M., et al. Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Experimental and Molecular Pathology 2010, 89:284-290.
261. Huang W.T., Weng S.W., Huang C.C., Lin H.C., Tsai P.C., Chuang J.H. Expression of Toll-like receptor9 in diffuse large B-cell lymphoma: further exploring CpG oligodeoxynucleotide in NFkappaB pathway. APMIS: Acta Pathologica, Microbiologica, and Immunologica Scandinavica 2012, 120:872-881.
262. Ntoufa S., Vardi A., Papakonstantinou N., et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Molecular medicine (Cambridge, MA) 2012, 18:1281-1291.